GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (STU:4E2) » Definitions » Other Current Receivables

Relmada Therapeutics (STU:4E2) Other Current Receivables : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Relmada Therapeutics Other Current Receivables?

Relmada Therapeutics's Other Current Receivables for the quarter that ended in Mar. 2024 was €0.00 Mil.

Relmada Therapeutics's annual Other Current Receivables increased from Dec. 2021 (€0.08 Mil) to Dec. 2022 (€0.48 Mil) but then declined from Dec. 2022 (€0.48 Mil) to Dec. 2023 (€0.00 Mil).


Relmada Therapeutics Other Current Receivables Historical Data

The historical data trend for Relmada Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relmada Therapeutics Other Current Receivables Chart

Relmada Therapeutics Annual Data
Trend Aug13 Jun15 Jun16 Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.07 0.08 0.48 -

Relmada Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Relmada Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


Relmada Therapeutics Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Relmada Therapeutics's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Relmada Therapeutics (STU:4E2) Business Description

Traded in Other Exchanges
Address
2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics (STU:4E2) Headlines

No Headlines